Ketryx, a provider of an agentic continuous compliance platform for safety-critical product development, announced that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors and participated in the company's Series B financing. The move underscores the growing need for automated compliance solutions as artificial intelligence becomes more prevalent in life sciences and other regulated industries.
Hawkins, who led Medtronic from 2007 to 2011 and served as chairman until 2014, brings extensive experience in navigating regulatory landscapes. His appointment comes as Ketryx aims to solve what it calls the "AI bottleneck" in life sciences—the challenge of integrating AI tools into development processes while maintaining compliance with stringent regulations from agencies like the FDA.
Ketryx's platform overlays existing tools used by engineering and quality teams to automatically generate compliant documentation, maintain continuous traceability, and enable safe and verifiable AI at scale. According to the company, its AI agents reduce manual work by up to 90 percent and help identify and close compliance gaps. The platform is trusted by four of the world's top five medical device manufacturers.
The life sciences industry faces increasing pressure to accelerate product development cycles while adhering to rigorous quality standards. Traditional compliance processes often involve manual documentation and fragmented systems, creating bottlenecks that delay time-to-market. Ketryx's approach aims to streamline these workflows by embedding compliance into the development process itself, allowing teams to focus on innovation rather than paperwork.
Hawkins' involvement signals confidence in Ketryx's vision and technology. "Bill's leadership at Medtronic and deep understanding of the regulatory environment make him an invaluable addition to our board," said a Ketryx spokesperson. "His insights will help us expand our impact across medical devices, pharmaceuticals, and robotics."
The Series B financing, which included Hawkins' participation, will likely be used to scale the platform and expand into new markets. Ketryx has not disclosed the amount raised, but the investment from a former Medtronic CEO adds credibility to its mission.
As AI adoption grows in health care and other safety-critical sectors, the ability to demonstrate compliance will become a competitive differentiator. Ketryx's platform addresses this need by providing a verifiable trail of development activities, which is essential for audits and regulatory submissions. By automating these processes, companies can reduce errors and accelerate approvals.
For more information about Ketryx and its platform, visit www.ketryx.com.
